Observational Study on Brain Metastases After Esophagectomy for Esophageal Cancer
This observational study, called METABREC, is looking into brain metastases (cancer that has spread to the brain) in patients who have had an esophagectomy (surgery to remove part of the esophagus) for esophageal cancer. Researchers want to understand if the number of patients developing brain metastases has increased, especially since new treatments before surgery (neoadjuvant treatment) have become more common. They are reviewing records of 10,000 patients who had surgery for esophageal cancer between 2000 and 2019. This includes patients with adenocarcinoma or squamous cell carcinoma. The main goal is to find the odds of developing brain metastases in this group.
- Study design
- This is an observational study looking at 10,000 patient records. It is not a clinical trial testing a new treatment.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study measures the odds of brain metastasis based on data collected between January 1, 2000, and March 1, 2020.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
At a glance
Conditions
NCT04654975
Where you'd take part
This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Amsterdam UMC
Amsterdam, Netherlandsno site contact published
Recruiting
Centre Hospitalier régional Universitaire de Lille
Lille, Franceno site contact published
Not yet recruiting
Erasmus MC
Rotterdam, Netherlandsno site contact published
Not yet recruiting
Karolinska Institutet
Stockholm, Swedenno site contact published
Recruiting
MD Anderson Cancer Center
Houston, Texasno site contact published
Not yet recruiting
Saint James Hospital
Dublin, Irelandno site contact published
Not yet recruiting
Universitair ziekenhuis Gent
Ghent, Belgiumno site contact published
Not yet recruiting
Zuyderland MC
Heerlen, Netherlandsno site contact published
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Lieven P Depypere, PhD · PRINCIPAL_INVESTIGATOR · UZ Leuven
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Odds ratio (OR) for brain metastasis1 January 2000 - 1 March 2020
Odds ratio (OR) for brain metastasis compared between primary surgery and neoadjuvant treatment plus surgery, OR for different neoadjuvant treatment regimes, corrected for gender and tumor factors (histology, stage, tumor differentiation,…) .